NCT03744403: A Phase I Study of CS1001 in Advanced Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with known, untreated, symptomatic central nervous system (CNS) metastases; Patients who have received prior therapies targeting PD-1, PD-L1, or CTLA-4

Comments are closed.

Up ↑